- Home
- JAZZ vs FRHC Comparison
JAZZ vs FRHC Comparison
Compare JAZZ & FRHC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | JAZZ | FRHC |
|---|---|---|
| Founded | 2003 | N/A |
| Country | Ireland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Bankers/Brokers/Service |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.8B | 8.7B |
| IPO Year | 2007 | N/A |
Fundamental Metrics
Financial Performance| Metric | JAZZ | FRHC |
|---|---|---|
| Price | $169.65 | $132.43 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 15 | 0 |
| Target Price | ★ $194.40 | N/A |
| AVG Volume (30 Days) | ★ 1.6M | 90.9K |
| Earning Date | 11-05-2025 | 11-07-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.08 |
| Revenue | ★ $4,157,832,999.00 | $1,563,510,000.00 |
| Revenue This Year | $6.00 | N/A |
| Revenue Next Year | $6.84 | N/A |
| P/E Ratio | ★ N/A | $1,722.97 |
| Revenue Growth | 4.14 | ★ 16.04 |
| 52 Week Low | $95.49 | $111.85 |
| 52 Week High | $182.99 | $194.01 |
Technical Indicators
Market Signals| Indicator | JAZZ | FRHC |
|---|---|---|
| Relative Strength Index (RSI) | 62.19 | 38.02 |
| Support Level | $164.44 | $131.00 |
| Resistance Level | $182.75 | $138.27 |
| Average True Range (ATR) | 5.88 | 4.52 |
| MACD | -1.21 | 0.91 |
| Stochastic Oscillator | 34.58 | 20.28 |
Price Performance
Historical ComparisonAbout JAZZ Jazz Pharmaceuticals plc (Ireland)
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
About FRHC Freedom Holding Corp.
Freedom Holding Corp is a holding company with its subsidiary it is engaged in securities brokerage, securities dealing for customers and account, market-making activities, investment research, investment counseling, investment banking services, retail and commercial banking, insurance products, payment services, and information processing services. It acts as a professional participant through its subsidiaries on the Kazakhstan Stock Exchange (KASE), Moscow Exchange (MOEX), Saint-Petersburg Exchange (SPB), the Ukrainian Exchange, the Uzbek Republican Currency Exchange (UZCE), and the Republican Stock Exchange of Tashkent (UZSE). Its segments are Brokerage, Banking, Insurance, and Others.